Table 1 Genes involved in PPGL pathogenesis

From: Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas

Gene

Frequency of mutations detected in PPGLs (mutation type)

Refs

ATRX

<5% (S)

96,98

BRAF

<2% (S)

15,45

CDKN2A

<2% (S)

96

EGLN1/PHD2

<1% (G or S)*

99,100

EPAS1

6–12% (M or S)

19,43,52,77

FGFR1

1% (S)

14

FH

1–2% (G)

24,43,101

H3F3A

<2% (M)*

14

HRAS

7–8% (S)

43,102

IDH2

<0.5% (S)

103

KIF1B

<5% (G or S)

18,104,105

KMT2D

<2% (G or S)*

106

MAX

1–2% (G or S)

107

MDH2

<2% (G)*

108

MERTK

<2% (G)*

14

MET

<2% (G) or <2–10% (S)*

14,96

NF1

3% (G) or 20–25% (S)

109,110

RET

5–6% (G or S)

44,111

SDHA

<1% (G or S)

112

SDHAF2

<1%

113

SDHB

8–10% (G)

43,111

SDHC

1–2% (G)

43,47,111

SDHD

5–7% (G)

43,111

TMEM127

1–2% (G)

43,114

TP53

<5% (S)

96

VHL

7–10% (G or S)

43,111

  1. The numbers shown here are in part based on data generated by the TCGA (The Cancer Genome Atlas) Research Network for Pheochromocytoma and Paraganglioma (unpublished data, publicly available through cBioPortal). G, germ line; S, somatic; M, mosaic; PPGLs, phaeochromocytomas and/or paragangliomas.
  2. *Frequency based on one or two clinical cases.
PowerPoint slide